title: Effects of estrogen replacement therapy on thrombin generation.
abstract: The aim of this study was to investigate the hemostatic system in menopausal women before and after three months of treatment with transdermal estradiol (TTS 50, 50 micrograms/die, n = 13) or coniugated equine estrogen (CEE, 0.625 mg/die, n = 9) by evaluating : beta-thromboglobulin, platelet factor 4, factor VIIag, factor VIIc, fibrinopeptide A-FPA-, thrombin-antithrombin-TAT-complexes, antithrombin-AT-activity, protein C, plasma fibrinolytic activity (euglobulin clot lysis time), plasminogen and antiplasmin activity. FPA levels significantly increased during TTS 50 treatment (p < 0.001) while protein C showed a slight but significant decrease in both treatments (TTS 50 p < 0.001, CEE p < 0.05). TAT complexes and AT were found unaltered. Platelet function and fibrinolytic activity did not significantly change. A significant relationship between FPA and estradiol levels, which were significantly increased during. TTS 50 therapy, was found (r = 0.40, p < 0.05). These findings indicate that unopposed estradiol given by transdermal route induces a slight but significant blood clotting activation, which seems strictly related to its biological activity.
authors.affiliation: Clinica Medical I, University of Florence, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Pinto
authors.forename: V
authors.initials: V
authors.lastname: Bruni
authors.forename: D
authors.initials: D
authors.lastname: Rosati
authors.forename: D
authors.initials: D
authors.lastname: Prisco
authors.forename: M
authors.initials: M
authors.lastname: Costanzo
authors.forename: B
authors.initials: B
authors.lastname: Giusti
authors.forename: R
authors.initials: R
authors.lastname: Abbate
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000032:analysis; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D001779:Blood Coagulation Factors; D004966:Estrogens, Conjugated (USP); D006062:Gonadotropins; D004958:Estradiol